Tags

Type your tag names separated by a space and hit enter

The evolution and origin of motor complications in Parkinson's disease.
Neurology. 2000; 55(11 Suppl 4):S13-20; discussion S21-3.Neur

Abstract

Levodopa is the major symptomatic therapy for Parkinson's disease (PD), having revolutionized the treatment of PD and provided benefit to virtually all patients. However, after 5-10 years of treatment, levodopa therapy is complicated by the development of motor complications, which include dyskinesia and motor fluctuations. The initial long duration response to a dose of levodopa becomes progressively shorter, and periods in which the patient responds to the drug become complicated by involuntary dyskinetic movements. Thus, patients may cycle between "on" periods that are complicated by dyskinesia and "off" periods in which they are severely parkinsonian. As a consequence they may experience profound disability despite the fact that levodopa remains an effective anti-parkinson agent throughout the course of the disease. In this article we review the various motor complications associated with the treatment of PD and present current concepts on the origin of these problems.

Authors+Show Affiliations

Department of Neurology and Neurosurgery, Clinica Universitaria and Medical School, University of Navarra, Pamplona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11147505

Citation

Obeso, J A., et al. "The Evolution and Origin of Motor Complications in Parkinson's Disease." Neurology, vol. 55, no. 11 Suppl 4, 2000, pp. S13-20; discussion S21-3.
Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology. 2000;55(11 Suppl 4):S13-20; discussion S21-3.
Obeso, J. A., Rodriguez-Oroz, M. C., Chana, P., Lera, G., Rodriguez, M., & Olanow, C. W. (2000). The evolution and origin of motor complications in Parkinson's disease. Neurology, 55(11 Suppl 4), S13-20; discussion S21-3.
Obeso JA, et al. The Evolution and Origin of Motor Complications in Parkinson's Disease. Neurology. 2000;55(11 Suppl 4):S13-20; discussion S21-3. PubMed PMID: 11147505.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The evolution and origin of motor complications in Parkinson's disease. AU - Obeso,J A, AU - Rodriguez-Oroz,M C, AU - Chana,P, AU - Lera,G, AU - Rodriguez,M, AU - Olanow,C W, PY - 2001/1/9/pubmed PY - 2001/2/28/medline PY - 2001/1/9/entrez SP - S13-20; discussion S21-3 JF - Neurology JO - Neurology VL - 55 IS - 11 Suppl 4 N2 - Levodopa is the major symptomatic therapy for Parkinson's disease (PD), having revolutionized the treatment of PD and provided benefit to virtually all patients. However, after 5-10 years of treatment, levodopa therapy is complicated by the development of motor complications, which include dyskinesia and motor fluctuations. The initial long duration response to a dose of levodopa becomes progressively shorter, and periods in which the patient responds to the drug become complicated by involuntary dyskinetic movements. Thus, patients may cycle between "on" periods that are complicated by dyskinesia and "off" periods in which they are severely parkinsonian. As a consequence they may experience profound disability despite the fact that levodopa remains an effective anti-parkinson agent throughout the course of the disease. In this article we review the various motor complications associated with the treatment of PD and present current concepts on the origin of these problems. SN - 0028-3878 UR - https://www.unboundmedicine.com/medline/citation/11147505/The_evolution_and_origin_of_motor_complications_in_Parkinson's_disease_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=11147505.ui DB - PRIME DP - Unbound Medicine ER -